Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "New Insights in Cancer Therapy and COVID Vaccination for Cancer Patients"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 4551
Special Issue Editors
Interests: immunotherapy; lung cancer; cancer vaccines; breast cancer; supportive care in oncology
Interests: antitumoral immunotherapy; circulating biomarker; thoracic oncology; cancer and lung fibrosis
Special Issue Information
Cancer immunotherapy has gained considerable popularity and momentum in recent years. Cancer vaccines, consisting of preventive and therapeutic vaccines, work by inducing or augmenting the immune response to enhance the immune system’s ability to fight cancer. Cancer vaccines are one of the main pillars of the cancer immunotherapy even in the era of checkpoint inhibitors. Indeed, although the latter have completely changed the scenario of cancer treatment, several types of patients do not benefit from them. However, the cancer vaccine field is still a work in progress because an effective strategy has not yet been developed.
In addition, Covid vaccination in cancer patients is getting a lot of attention in the academic community. Some scholars think that cancer patients should be prioritized to receive the vaccine.
The topic of the Special Issue will cover cancer vaccine research, cancer immunotherapy research, and Covid vaccination research in cancer patients.
Prof. Laurent Zelek
Dr. Boris Duchemann
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer vaccines
- cancer immunotherapy
- Covid vaccination